NASDAQ:MOR MorphoSys (MOR) Stock Forecast, Price & News $7.90 +0.17 (+2.20%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$7.61▼$8.0650-Day Range$7.19▼$8.6052-Week Range$3.17▼$8.67Volume234,845 shsAverage Volume140,192 shsMarket CapitalizationN/AP/E Ratio18.37Dividend YieldN/APrice Target$12.81 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MorphoSys MarketRank™ ForecastAnalyst RatingHold2.22 Rating ScoreUpside/Downside62.2% Upside$12.81 Price TargetShort InterestBearishDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.94) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector682nd out of 961 stocksPharmaceutical Preparations Industry321st out of 453 stocks 3.1 Analyst's Opinion Consensus RatingMorphoSys has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 4 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.81, MorphoSys has a forecasted upside of 62.2% from its current price of $7.90.Amount of Analyst CoverageMorphoSys has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverMorphoSys has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MorphoSys has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphoSys does not currently pay a dividend.Dividend GrowthMorphoSys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOR. Previous Next 2.5 News and Social Media Coverage News SentimentMorphoSys has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MorphoSys this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added MorphoSys to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MorphoSys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of MorphoSys is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for MorphoSys are expected to decrease in the coming year, from ($1.94) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MorphoSys is 18.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.78.Price to Earnings Ratio vs. SectorThe P/E ratio of MorphoSys is 18.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.52.Price to Book Value per Share RatioMorphoSys has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MorphoSys (NASDAQ:MOR) StockMorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comMorphoSys (NASDAQ:MOR) Sees Large Volume IncreaseSeptember 16, 2023 | americanbankingnews.comMorphoSys (NASDAQ:MOR) Lifted to Neutral at The Goldman Sachs GroupSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 15, 2023 | morningstar.comMorphoSys shares gain as endometrial cancer treatment gets fast-track designationSeptember 12, 2023 | markets.businessinsider.comMorphoSys Gets U.S. FDA Fast Track Designation For Tulmimetostat In Endometrial CancerSeptember 12, 2023 | finance.yahoo.comGlobal Antibodies Market Set to Soar, Projected to Reach $524.8 Billion by 2030 with a CAGR of 12.9%September 12, 2023 | markets.businessinsider.comEQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial CancerSeptember 12, 2023 | finance.yahoo.comMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial CancerSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 12, 2023 | msn.comGermany stocks lower at close of trade; DAX down 0.54%September 11, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: ALX Oncology Holdings (ALXO), Sanofi (SNYNF)September 5, 2023 | finance.yahoo.comIs MorphoSys AG (MOR) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapSeptember 5, 2023 | msn.comMorphoSys: Pelabresib Data Coming Out Soon, More Room To RunAugust 18, 2023 | msn.comMorphoSys: Stable Liquidity Amid Challenging MarketsAugust 11, 2023 | marketwatch.comUS Futures Up, European Stocks Down as Market Weighs US DataAugust 11, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Morphosys Ag (MOR)August 10, 2023 | seekingalpha.comMorphoSys AG 2023 Q2 - Results - Earnings Call PresentationAugust 10, 2023 | nasdaq.comDAX Gains Ahead Of US Inflation DataAugust 10, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Moderately Higher ThursdayAugust 10, 2023 | marketwatch.comMorphosys Net Loss Narrows as Lower Costs Offset Sales DeclineAugust 9, 2023 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsAugust 9, 2023 | msn.comCrescent Energy Company GAAP EPS of $0.11 misses by $0.01, revenue of $492.3M beats by $19.56MAugust 9, 2023 | markets.businessinsider.comMorphoSys Q2 Loss NarrowsAugust 9, 2023 | msn.comMorphoSys GAAP EPS of -€$2.16, revenue of €$53.2MAugust 9, 2023 | finance.yahoo.comMorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsAugust 8, 2023 | markets.businessinsider.comWhat Wall Street expects from MorphoSys's earningsJuly 28, 2023 | finance.yahoo.comGlobal Idiopathic Membranous Nephropathy (IMN) Market Study 2023-2032: Breakthrough Therapies Offer Hope for IMN PatientsSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address MOR Company Calendar Last Earnings8/09/2023Today9/21/2023Next Earnings (Estimated)11/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MOR CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees544Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.81 High Stock Price Forecast$17.00 Low Stock Price Forecast$9.25 Forecasted Upside/Downside+62.2%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.43 Trailing P/E Ratio18.37 Forward P/E RatioN/A P/E GrowthN/ANet Income$-159,150,000.00 Net Margins27.67% Pretax Margin92.61% Return on Equity154.85% Return on Assets3.33% Debt Debt-to-Equity Ratio7.56 Current Ratio3.57 Quick Ratio3.27 Sales & Book Value Annual Sales$292.84 million Price / Sales3.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book6.53Miscellaneous Outstanding Shares136,930,000Free FloatN/AMarket Cap$1.08 billion OptionableNot Optionable Beta1.09 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 58)Chairman of Management Board, MD & CEO Comp: $2.2MDr. Lucinda Crabtree Ph.D. (Age 44)CFO & Member of Management Board Ms. Charlotte Lohmann (Age 53)Chief Legal Officer & Member of Management Board Mr. Klaus De WallHead of Accounting & TaxMs. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.Dr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Anja PomrehnSr. VP & Head of Investor RelationsMr. Thomas BiegiVP & Head of Corp. CommunicationsMs. Maria CastresanaSr. VP & Global Head of HRDr. Barbara Krebs-Pohl Ph.D.Chief Bus. OfficerMore ExecutivesKey CompetitorsAptinyxNASDAQ:APTXGH ResearchNASDAQ:GHRSInterCureNASDAQ:INCRLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInstitutional OwnershipHudson Bay Capital Management LPSold 262,500 shares on 8/15/2023Ownership: 0.000%Point72 Asset Management L.P.Bought 218,700 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 48,332 shares on 8/15/2023Ownership: 0.000%Citadel Advisors LLCBought 2,600 shares on 8/15/2023Ownership: 0.000%Artia Global Partners LPBought 43,499 shares on 8/14/2023Ownership: 0.000%View All Institutional Transactions MOR Stock - Frequently Asked Questions Should I buy or sell MorphoSys stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares. View MOR analyst ratings or view top-rated stocks. What is MorphoSys' stock price forecast for 2023? 9 brokers have issued 1-year price targets for MorphoSys' stock. Their MOR share price forecasts range from $9.25 to $17.00. On average, they expect the company's stock price to reach $12.81 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for MOR or view top-rated stocks among Wall Street analysts. How have MOR shares performed in 2023? MorphoSys' stock was trading at $3.58 at the start of the year. Since then, MOR stock has increased by 120.7% and is now trading at $7.90. View the best growth stocks for 2023 here. When is MorphoSys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023. View our MOR earnings forecast. How were MorphoSys' earnings last quarter? MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $57.91 million for the quarter. MorphoSys had a net margin of 27.67% and a trailing twelve-month return on equity of 154.85%. What ETF holds MorphoSys' stock ? Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio. What is Simon E. Moroney's approval rating as MorphoSys' CEO? 5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did MorphoSys IPO? (MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. What is MorphoSys' stock symbol? MorphoSys trades on the NASDAQ under the ticker symbol "MOR." Who are MorphoSys' major shareholders? MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Hudson Bay Capital Management LP (0.00%), Point72 Asset Management L.P. (0.00%), Marshall Wace LLP (0.14%), Tekla Capital Management LLC (0.13%), Wells Fargo & Company MN (0.00%) and Artia Global Partners LP (0.00%). How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MorphoSys' stock price today? One share of MOR stock can currently be purchased for approximately $7.90. How much money does MorphoSys make? MorphoSys (NASDAQ:MOR) has a market capitalization of $1.08 billion and generates $292.84 million in revenue each year. The company earns $-159,150,000.00 in net income (profit) each year or $0.43 on an earnings per share basis. How many employees does MorphoSys have? The company employs 544 workers across the globe. How can I contact MorphoSys? MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The official website for the company is www.morphosys.com. The company can be reached via phone at (498) 989-9270, via email at investors@morphosys.com, or via fax at 49-89-8992-7222. This page (NASDAQ:MOR) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.